Enveric Biosciences Inc. (ENVB)
NASDAQ: ENVB
· Real-Time Price · USD
1.08
-0.03 (-2.70%)
At close: Aug 15, 2025, 3:57 PM
1.09
0.98%
After-hours: Aug 15, 2025, 07:16 PM EDT
Enveric Biosciences Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -2.18M | -3.15M | -2.08M | -1.88M | -2.46M | -3.44M | -2.82M | -6.36M | -4.68M | -8.68M | -2.48M | -2.79M | -4.52M | -42.11M | -2.71M | -908.29K | -3.25M |
Depreciation & Amortization | 42.18K | 82.49K | -43.62K | 84.78K | 85.41K | 84.68K | 95.84K | 114.37K | 113.33K | 90.42K | 121.1K | 119.96K | 103.72K | 197.26K | 173.7K | 174.02K | 136.64K |
Stock-Based Compensation | 193.85K | 471.68K | 369.61K | 369.61K | 351.49K | 364.73K | 372.86K | 879.74K | 532.84K | 529.37K | 645.14K | 677.54K | 768.62K | 7.77M | 486.99K | 750.93K | 3.59M |
Other Working Capital | n/a | 415.06K | 2.2M | -1.45M | -759.29K | 739.38K | 356.34K | 409.58K | -653.71K | 368.1K | 259.22K | -481.35K | -627.32K | -144K | 510.88K | -124.55K | -66.21K |
Other Non-Cash Items | n/a | 411.6K | 129.06K | -18.57K | 298.47K | 2.1M | 2.73M | 597.75K | -183.16K | 3.86M | -3.18M | -1.92M | -275.97K | 37.29M | -804.83K | -2.46M | 298.71K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | -1.07M | -3.36M | n/a | n/a | n/a | n/a | n/a | n/a | -7.45M | n/a | n/a | -3.81M |
Change in Working Capital | n/a | 877.34K | 701.91K | -1.45M | -556.89K | 205.84K | 243.63K | 298.27K | -922.49K | 738.46K | 340.45K | -675.27K | -621.3K | 239.2K | 650.35K | 421K | -125.49K |
Operating Cash Flow | -2.39M | -1.31M | -927.07K | -2.89M | -2.6M | -1.75M | -2.74M | -4.47M | -5.14M | -3.46M | -4.55M | -4.59M | -4.55M | -4.07M | -2.21M | -2.02M | -3.16M |
Capital Expenditures | n/a | n/a | -3 | 3.00 | n/a | 15.00 | -8 | -18 | -5.17K | -6.19K | -18.57K | -53.89K | -505.51K | -189.72K | n/a | n/a | -675K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | -53 | 28.00 | 16.87K | n/a | n/a | n/a | 958.04K | n/a | n/a | 3.06M | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | -0.05 | 0.03 | 16.87 | n/a | -584.16K | n/a | -958.04K | n/a | 0.00 | 3.06M | n/a | -675 |
Investing Cash Flow | n/a | n/a | n/a | n/a | n/a | -38 | 20.00 | 16.85K | -5.17K | -6.19K | -18.57K | -53.89K | -505.51K | -189.72K | 3.06M | n/a | -675K |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | 1.08M | n/a | n/a | n/a | 1.05M | n/a | -1.05M | n/a | n/a | n/a | n/a | n/a | n/a | -0.01 | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 75.04K | 1.78M | -149 | -17.25K | 2.53M | -186.08K | -105K | n/a | n/a | n/a | n/a | 958.04K | n/a | 7.00 | -9 | 17.93K | 3.27M |
Financial Cash Flow | 4.45M | 463.45K | 517.69K | 34.43K | 6.66M | -186.08K | -105K | -1.05M | n/a | n/a | 7.82M | 958.04K | 9.4M | 7.00 | -9 | 17.93K | 24.88M |
Net Cash Flow | 2.05M | -870.66K | -390.87K | -2.85M | 4.07M | -1.98M | -2.81M | -5.48M | -5.16M | -3.48M | 3.19M | -3.69M | 4.34M | -4.09M | 830.51K | -2.04M | 21.08M |
Free Cash Flow | -2.39M | -1.31M | -927.07K | -2.89M | -2.6M | -1.75M | -2.74M | -4.47M | -5.14M | -3.47M | -4.57M | -4.64M | -5.05M | -4.26M | -2.21M | -2.02M | -3.84M |